Robert J. Calcaterra

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Immunovalent Therapeutics, Inc. is a medicine company harnessing microfluidic technology for the treatment of cancer immunotherapy. The company is headquartered in St. Louis, MO.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Immunovalent Therapeutics, Inc. is a medicine company harnessing microfluidic technology for the treatment of cancer immunotherapy. The company is headquartered in St. Louis, MO.

Immunovalent Therapeutics, Inc. is a medicine company harnessing microfluidic technology for the treatment of cancer immunotherapy. The company is headquartered in St. Louis, MO.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.